Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

European Journal of Haematology

Volumn 69, Issue 1, 2002, Pages 11-20

  Räty, Riikka ^a   Franssila, Kaarle ^a   Joensuu, Heikki ^a   Teerenhovi, Lasse ^a   Elonen, Erkki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Histopathology; International Prognostic Index; Mantle cell lymphoma; Prognosis; Proliferation

Indexed keywords

KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MITOSIS RATE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TIME SERIES ANALYSIS;

AGED; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036660406     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01677.x     Document Type: Article

References (42)

1. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-640.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
3. Zucca E, Stein H, Coiffier B, European Lymphoma Task Force (ELTF). Report of the workshop on Mantle Cell Lymphoma (MCL). Ann Oncol 1994;5:507-511.
4. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CD5-expressing B-cell non-Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995;85:1570-1579.
5. Rimokh R, Berger F, Cornillet P, et al. Break in the BCL1 locus is closely associated with intermediate lymphocytic lymphoma subtype. Genes Chromosomes Cancer 1990;2:223-226.
6. Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood 1991;78:493-498.
7. Garcia-Conde J, Cabanillas F. Mantle cell lymphoma: a lymphoproliferative disorder associated with aberrant function of the cell cycle. Leukemia 1996;10:s78-s83.
8. De Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995;86:2715-2723.
9. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000;95:2253-2261.
10. De Wolf-Peeters C, Pittaluga S. Mantle-cell lymphoma. Ann Oncol 1994;5:35-37.
11. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:1075-1082.
12. Norton AJ, Matthews J, Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995;6:249-256.
13. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
14. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14:1269-1274.
15. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma, clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329-336.
16. Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567-575.
17. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995;13:2819-2826.
18. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
19. Ott G, Kalla J, Hanke A, et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma 1998;32:55-63.
20. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
21. Bernard M, Gressin R, Lefrére F, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001;15:1785-1791.
22. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997;15:1664-1671.
23. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma, a retrospective study of 121 cases. Leukemia 1998;12:1281-1287.
24. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190-196.
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
26. International Agency for Research on Cancer (IARC). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization 2001 Classification of Tumours. Lyon: IARC Press, 2001:168-170.
27. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
29. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
30. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-127.
31. Duggan MJ, Weisenburger DD, Ye YL, et al. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 1990;66:522-529.
32. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer 1982;49:1429-1438.
33. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990;14:752-763.
34. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997;89:1421-1429.
35. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000;95:619-626.
36. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-2732.
37. Jares P, Campo E, Pinyol M, et al. Expression of retino-blastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol 1996;148:1591-1600.
38. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14) (q13;q32). Blood 1995;86:2892-2899.
39. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-3359.
40. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302-4310.
41. Zoldan MC, Inghirami G, Masuda Y, et al. Large-cell variants of mantle cell lymphoma. cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996;93:475-486.
42. Hermans J, Krol AD, Van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463.